Update on pharmacologic therapy for chronic obstructive pulmonary disease.
As described throughout this article, significant improvements continue to occur in the pharmacologic management of COPD. These improvements range from improved medication targeting to better understanding of mechanisms of action, to better delivery of medications, to lower side effects. New areas of pharmacologic intervention, if not ready for use today, hold great promise for the not-too-distant future. In addition to the many agents described here, multiple mediator antagonists and anti-inflammatory agents are also under investigation for use in COPD. Interestingly, repair of alveolar tissue may be possible. Indeed, preliminary animal studies suggest that retinoic acid may be able to induce regeneration of lung alveoli. Overall, more effort is needed to broaden awareness and provide for the appropriate diagnosis of COPD, better explain pharmacologic therapies for COPD, simplify and disseminate guidelines, and highlight key differences between asthma and COPD, including their treatment strategies. As interest in COPD continues to grow, future updates on COPD management will continue to add new pharmacologic options for this devastating and preventable disease.
Ferguson
G T
GT
Department of Anatomy and Cell Biology, Wayne State University School of Medicine, Detroit, Michigan, USA. gferguson@botsford.org
D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000318:Adrenergic beta-Agonists / Q000627:therapeutic use*; D018680:Cholinergic Antagonists / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D006801:Humans; D008173:Lung Diseases, Obstructive / Q000188:drug therapy* / Q000628:therapy; D009748:Nutrition Disorders; D011660:Pulmonary Heart Disease / Q000188:drug therapy; D011788:Quality of Life; D016540:Smoking Cessation / Q000379:methods; D014611:Vaccination; D014970:Xanthines / Q000627:therapeutic use; D019896:alpha 1-Antitrypsin Deficiency / Q000188:drug therapy
D000305:Adrenal Cortex Hormones; D000318:Adrenergic beta-Agonists; D018680:Cholinergic Antagonists; D014970:Xanthines; C008514:methylxanthine